SecSonar.com

Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Revolution Medicines, Inc. (RVMD) is a Biotechnology company based in US with a market capitalization of $33.3B. Free cash flow was negative at -$913.7M. This page tracks RVMD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 616 employees · IPO Feb 13, 2020

Valuation

Valuation & price

$145.66 · as of May 17, 2026 · -24.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

20.41

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$189$112$34.70Jul 25Dec 25Jul 26Jul 7, 25$36.67Jul 9, 25$38.52Jul 11, 25$38.02Jul 15, 25$37.81Jul 17, 25$39.05Jul 21, 25$38.42Jul 23, 25$37.53Jul 25, 25$37.91Jul 29, 25$37.01Jul 31, 25$37.27Aug 4, 25$37.18Aug 6, 25$36.67Aug 11, 25$34.70Aug 13, 25$36.07Aug 15, 25$36.32Aug 19, 25$36.54Aug 21, 25$36.48Aug 25, 25$35.67Aug 27, 25$38.04Aug 29, 25$37.97Sep 3, 25$39.77Sep 5, 25$40.50Sep 9, 25$40.94Sep 11, 25$46.24Sep 16, 25$44.70Sep 18, 25$45.22Sep 22, 25$44.41Sep 24, 25$43.54Sep 26, 25$43.92Sep 30, 25$46.70Oct 2, 25$45.70Oct 6, 25$46.58Oct 8, 25$47.82Oct 10, 25$48.24Oct 14, 25$47.50Oct 16, 25$49.68Oct 21, 25$53.49Oct 23, 25$53.44Oct 27, 25$57.99Oct 29, 25$58.02Oct 31, 25$58.84Nov 4, 25$58.57Nov 6, 25$61.38Nov 10, 25$62.73Nov 12, 25$65.83Nov 14, 25$67.75Nov 18, 25$70.58Nov 20, 25$69.88Nov 25, 25$76.32Nov 28, 25$77.76Dec 2, 25$75.31Dec 4, 25$78.48Dec 8, 25$80.06Dec 10, 25$77.88Dec 12, 25$78.92Dec 16, 25$77.56Dec 18, 25$75.96Dec 22, 25$80.58Dec 24, 25$81.19Dec 29, 25$80.52Jan 2, 26$79.02Jan 6, 26$79.85Jan 8, 26$107.39Jan 12, 26$117.17Jan 14, 26$121.22Jan 16, 26$120.28Jan 21, 26$117.53Jan 23, 26$117.63Jan 27, 26$99.82Jan 29, 26$98.20Feb 2, 26$97.16Feb 4, 26$96.51Feb 9, 26$96.74Feb 11, 26$97.99Feb 13, 26$96.31Feb 18, 26$99.79Feb 20, 26$101.83Feb 24, 26$104.83Feb 26, 26$102.15Mar 2, 26$101.62Mar 4, 26$101.19Mar 6, 26$98.40Mar 10, 26$98.86Mar 12, 26$95.07Mar 17, 26$99.13Mar 19, 26$99.29Mar 23, 26$96.63Mar 25, 26$94.29Mar 27, 26$92.51Mar 31, 26$97.25Apr 2, 26$99.12Apr 7, 26$96.29Apr 9, 26$96.22Apr 13, 26$136.30Apr 15, 26$152.54Apr 17, 26$148.63Apr 22, 26$141.50Apr 24, 26$135.30Apr 28, 26$144.83Apr 30, 26$144.12May 4, 26$147.90May 6, 26$151.07May 8, 26$141.81May 12, 26$145.72May 14, 26$149.47May 18, 26$144.37May 20, 26$150.33May 22, 26$151.56May 28, 26$154.63Jun 1, 26$163.68Jun 3, 26$155.99Jun 5, 26$149.23Jun 9, 26$149.55Jun 11, 26$149.23Jun 15, 26$160.06Jun 17, 26$157.77Jun 22, 26$165.81Jun 24, 26$169.77Jun 26, 26$182.08Jul 2, 26$189.24
$34.7052-week range$192.62
Loading valuation history…

Fundamentals

Key fundamentals

$33.3B

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$913.7M

Free cash flow (USD)

-$1.9B

Net debt

Net cash position

13.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$0.00FY 2018$20.2MFY 2019$50.0MFY 2020$43.0MFY 2021$29.4MFY 2022$35.4MFY 2023$11.6MFY 2024$0.00FY 2025$0.00
$0$0

Free cash flow by year

2017 → 2025

FY 2017$-26.7MFY 2018$-286.0KFY 2019$-52.2MFY 2020$-103.0MFY 2021$-153.7MFY 2022$-235.2MFY 2023$-358.3MFY 2024$-567.7MFY 2025$-913.7M
-$26.7M-$913.7M

Gross margin by year

2021 → 2023

FY 2021100.0%FY 2022100.0%FY 2023100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.0M · 10b5-1 PlanPatel Sushil · Director · $1MJul 1, 2026Filing
  • 8-K eventExecutive RetirementJun 22, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventConvertible Notes IssuedApr 17, 2026Filing
  • 8-K eventCommon Stock OfferingApr 16, 2026Filing
  • 8-K eventClinical Trial ResultsApr 13, 2026Filing

Questions

Frequently asked questions

What is Revolution Medicines, Inc.'s market cap?

Revolution Medicines, Inc. (RVMD) has a market capitalization of $33.3B.

What is RVMD's P/E ratio?

A meaningful P/E ratio is not available for RVMD — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is RVMD's price-to-book (P/B) ratio?

RVMD trades at 20.41 times book value per share.

Are insiders buying RVMD stock?

SEC Form 4 filings show no open-market insider buys at Revolution Medicines, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

ALNY

Alnylam Pharmaceuticals, Inc.

$40.3B

RPRX

Royalty Pharma plc

$23.6B

UTHR

United Therapeutics Corporation

$23.4B

INSM

Insmed Incorporated

$23.3B

ROIV

Roivant Sciences Ltd.

$21.7B

INCY

Incyte Corporation

$19.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.